Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed an informed consent form agreeing to take part in the study.
• People diagnosed with a type of blood cancer called CD20-positive diffuse large B-cell lymphoma, mantle cell lymphoma, or indolent (slow-growing) lymphoma that has come back or stopped responding to treatment.
• People whose cancer has returned or stopped responding after at least two previous treatments, and for whom no curative treatment is available — specifically those who are not eligible for a currently approved CAR T cell therapy that targets CD19, those whose cancer cells no longer have the CD19 marker, or those whose cancer came back after receiving CD19 CAR T cell therapy.
• In the first phase of the trial, people over 18 years old; in the second phase, people of all ages.
• People whose cancer can be measured using standard imaging criteria (called the Lugano classification).
• People who are reasonably well and able to carry out daily activities (based on a standard medical fitness scale called ECOG 0–2).
• People whose bone marrow is functioning well enough, shown by blood test results meeting minimum levels for certain blood cell counts (neutrophils, platelets, and lymphocytes).
• People whose kidneys, liver, heart, and lungs are functioning well enough, based on specific blood and heart test results meeting minimum thresholds.
• People with suitable veins for receiving the study treatment by intravenous drip.
• People who are capable of having children must agree to use contraception throughout the trial.

Who may not be able to join:

• People with certain other types of CD20-positive lymphoma, including Burkitt lymphoma, primary CNS lymphoma, plasmablastic lymphoma, or CLL that has transformed into another type of lymphoma (called Richter transformation).
• People with a significant medical or psychiatric condition that would make it difficult to understand and consent to the trial, or to follow the study procedures.
• People with a known HIV (human immunodeficiency virus) infection.
• People whose disease is at immediate risk of affecting the function of vital organs.
• People whose cancer is progressing very rapidly.
• People with a currently active or severe infection, such as tuberculosis, sepsis, serious opportunistic infections, or active hepatitis B or hepatitis C.
• People with other serious underlying health conditions that, in the clinical team's judgement, could make it unsafe to receive the treatment.
• People who have received another experimental treatment within 30 days before enrolling in this trial.
• People who may have a sensitivity or allergic reaction to tocilizumab or any other agent used in this study.
• People who have taken high-dose steroid tablets (more than 10mg per day) within 5 days before starting the study treatment, or within 7 days before a procedure to collect immune cells (called leukapheresis).
• People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.